Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sapanisertib and Serabelisib vs Everolimus in Metastatic Clear-Cell RCC
NCT02724020Phase 2Completed
- Sponsor
- Millennium Pharmaceuticals
- Start
- Jun 2016
- Primary completion
- Feb 2020
- Modality
- Small Molecules
- Countries
- 8
01
Overview
A Phase 2 trial of sapanisertib, serabelisib in clear cell renal cell carcinoma (ccRCC), sponsored by Millennium Pharmaceuticals. Started Jun 2016; status: completed.
02
Drugs
sapanisertibserabelisib
03
Conditions
clear cell renal cell carcinoma (ccRCC)
Beyond the preview
Go deeper on NCT02724020.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02724020.